TESARO price target raised to $51 from $43 at RW Baird Baird raised its price target on TESARO following its announced move into the immune-oncology space. The firm likes the deal and believes its fits nicely along its other businesses. Shares remain Outperform rated.
TESARO price target raised to $50 from $44 at Mizuho Mizuho raised its price target for TESARO shares to $50 citing increased confidence and market opportunity for niraparib following the company's Q4 results. The firm expects approval for rolapitant in Q3 and reiterates a Buy rating on the stock.